Submitted by Anonymous (not verified) on 22 May 2026 - 11:32
Orphan designation: bevacizumab Treatment of hereditary haemorrhagic telangiectasia, 16/12/2014 Positive
Source:
Orphan designation: bevacizumab Treatment of hereditary haemorrhagic telangiectasia, 16/12/2014 Positive